Concepedia

Mark Fineman

MF

45

Publications

10.7K

Citations

35

H-Index

1992

Active since

Affiliations

Amplyx Pharmaceuticals (United States)(Current)

Eli Lilly (United States)

MedStar Health

University of California San Diego

University of North Carolina at Chapel Hill

Mark Fineman is an author at Amplyx Pharmaceuticals (United States) specializing in medicine, pharmacology, and diabetes.

ORCID

Top concepts

Publications per year

1992–2023

45

Publications

45

Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes

Ralph A. DeFronzo, Robert E. Ratner, Jenny Han et al. · Diabetes Care · 2005 · 1.5K citations

Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes

John B. Buse, Robert R. Henry, Jenny Han et al. · Diabetes Care · 2004 · 1.3K citations · Full text

Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea

David M. Kendall, Matthew C. Riddle, Julio Rosenstock et al. · Diabetes Care · 2005 · 1.2K citations · Full text

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

John B. Buse, Michael A. Nauck, Thomas Först et al. · The Lancet · 2012 · 559 citations

, , +5

Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes

Orville Kolterman, John B. Buse, Mark Fineman et al. · The Journal of Clinical Endocrinology & Metabolism · 2003 · 551 citations · Full text

Rows per page

1–5 of 45